Japan 2022 Review/Outlook: Supply Crisis, Incentives, Cost Controls In Focus
Balance Of Give And Take
Executive Summary
As Japan's pharma market continues to face supply chain challenges and rising healthcare costs, regulatory authorities are looking to policies that balance incentives in critical areas and temporary price rises with other other ongoing measures to contain the national drugs bill. The Pink Sheet takes a look at the key changes last year and what to expect in 2023.
You may also be interested in...
Japan Lays Out New Antibiotics Plan As It Addresses Resistance Issues
A new five-year strategic plan to counter antimicrobial resistance includes concrete new goals to reduce rates of resistance to specific drugs and support the development of new products.
Third Time Lucky As Japan Finally Approves Shionogi’s Oral COVID Antiviral
Shionogi’s once-daily oral COVID-19 antiviral finally gets Japan approval after being considered for the third time by an expert panel, paving the way for public availability of the country’s first such home-grown option in early December.
PhRMA Promotes Cluster Concept In Japan Reform Wish List
US industry association promotes an exchanges with Japan on bioclusters, while continuing to push for holistic debate on reforms to the country’s national healthcare system and changes to reimbursement pricing it sees as supporting innovation.